Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Maxamine histamine dihydrochloride: Phase III

In MAXM's 305-patient U.S. Phase III trial, the combination of Maxamine plus IL-2 met one of two primary end points of a significant increase in survival duration compared

Read the full 284 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE